Duality of Interest. R.A. has received nonfinancial support and consulting fees from Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Intercept, and Novartis; has received royalties or licenses from UptoDate and Wolters Kluwer; is a member of data safety monitoring committees for Chinook and Vertex; has served as an associate editor of the American Journal of Nephrology and Nephrology Dialysis Transplantation ; has been an author and editor for UpToDate; and has received research grants from the National Institutes of Health and the US Veterans Administration. J.B.G. has received funds for research, paid to her institution, from Bluedrop, Boehringer Ingelheim, Eli Lilly, Merck, and Roche and is a consultant for Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Eli Lilly, Mineralys, Novo Nordisk, Valo, and Vertex. H.J.L.H. has received consulting fees from Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, BioCity, Dimerix, Eli Lilly, Janssen, Novartis, Novo Nordisk, Roche, and Travere Therapeutics, all paid to his employer; research support from AstraZeneca, Boehringer Ingelheim, Bayer, Janssen, and Novo Nordisk, all paid to his employer; honoraria from AstraZeneca and Novo Nordisk; and travel expenses from AstraZeneca and Eli Lilly. J.F.E.M. has received grants from McMaster University, Novo Nordisk, and the European Union; has received consulting fees from Bayer and Novo Nordisk; has received honoraria from AstraZeneca, Bayer, Novartis, UpToDate, and Novo Nordisk; has participated on a data safety monitoring board for Cytel, IQVIA, Parexel, WCG, and Sanofi; and had a leadership role in the Kidney Disease: Improving Global Outcomes group. J.B.M. is the principal investigator on grants to Washington University from Biomea Fusion, Diamyd, Breakthrough T1D (formerly JDRF), Lexicon, the National Institutes of Health, and Novo Nordisk; has received royalties or licenses from Washington University; has received consulting fees from Bayer, ClearNote Health, Eli Lilly, Mannkind, Novo Nordisk, and Thermo Fisher Scientific; has received payment or honoraria from Medscape, Thermo Fisher Scientific, Bayer, Med Learning Group, and Baylor; has participated on a data safety monitoring board for the Jaeb Center, Washington University, and the National Institutes of Health; has received support for attending meetings and/or travel from the Endocrine Society, Mannkind, Western Endocrine Society, and Kansas Diabetes Symposium; and holds a leadership or fiduciary role with the Diabetes Technology Access Group. A.K.M. has received research support and personal fees from Alexion, Boehringer Ingelheim, Bayer, Chinook Therapeutics, and Novartis, paid to her institution; royalties from UpToDate; consulting fees from Bayer, Otsuka, Vera, and Chinook/Novartis; and travel support and payment for an educational symposium from Novo Nordisk. M.N. has received research grants from Astellas, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, JT, Kyowa-Kirin, Takeda, Tanabe-Mitsubishi, and Torii; consulting fees from Astellas, Boehringer Ingelheim, Daiichi Sankyo, JT, Kyowa-Kirin, and Tanabe-Mitsubishi; and honoraria from Astellas, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, GSK, Kyowa-Kirin, and Tanabe-Mitsubishi. J.R. has received research grants from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Carmot, Corcept, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Regeneron, Pfizer, and Sanofi; has served on scientific advisory boards and received honoraria or consulting fees from Amgen, Applied Therapeutics, Biomea Fusion, Eli Lilly, Hanmi, Novo Nordisk, Oramed, Regeneron, Regor, Roche, Sanofi, and Structure Therapeutics; and has received honoraria for lectures from Eli Lilly, Novo Nordisk, and Sanofi. M.V. has received research grant support, served on advisory boards, or had speaker engagements with Alnylam Pharmaceuticals, American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Bristol Myers Squibb, Boehringer Ingelheim, Chiesi, Cytokinetics, Esperion, Fresenius Medical Care, Idorsia Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Milestone Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health and participates on clinical trial committees for studies sponsored by Amgen, AstraZeneca, Boehringer Ingelheim, Galmed, Novartis, Bayer AG, Occlutech, Pharmacosmos, and Impulse Dynamics. M.B. is an employee of Bayer AG, Germany, and is named on a planned, issued, or pending finerenone patent. C.S. is an employee of Bayer Healthcare Inc, USA. L.L. is an employee of Bayer AG, Germany. N.L. is an employee of Bayer Healthcare, China. K.R. is an employee of Bayer AG, Germany. P.R. has received research support from AstraZeneca, Bayer, and Novo Nordisk, all to his institution; consulting fees from Abbott, Amgen, Astellas, Bayer, Boehringer Ingelheim, Eli Lilly, Roche, and Gilead, all to his institution; payment or honoraria from Daiichi Sankyo to his institution; support for attending meetings and/or travel from Bayer; and receipt of study drug for an investigator-initiated study from Bayer, AstraZeneca, Novo Nordisk, and Lexicon Pharma. No other potential conflicts of interest relevant to this article were reported.
PubMed
